The Effect Of Doluxetine On The Treatment Of Neuropathy Induced By Paclitaxol In Breast Cancer Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180805040700N1

Enrollment

Registered

2018-12-06

Start date

2018-09-23

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Control group: in the control group , patients treated with placebo, prepared by the pharmacist, will be examined in terms of their shape and color and the same size as doluxetine and

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Persons over 18 years of age Good co-operation Patients with breast cancer under the first course of paclitaxel therapy People under the age of 75

Exclusion criteria

Exclusion criteria: intolerance of duloxetine

Design outcomes

Primary

Measure	Time frame
Neuropathy. Timepoint: first referral of patients and 12 weeks after start intervention. Method of measurement: Patient Neurotoxicity Questionnaire = PNQ, EMG-NCV of the four limbs Amplitude and latency analysis of mental and movement neurals of lower and lower fever.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Arjomandzadegan

Arak University of Medical Sciences

Arjomandzadegan@arakmu.ac.ir+98 86 3367 5003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026